BeOne Medicines Ltd. (ONC)
NASDAQ: ONC
· Real-Time Price · USD
341.37
-3.80 (-1.10%)
At close: Oct 03, 2025, 2:24 PM
-1.10% (1D)
| Bid | 241.28 |
| Market Cap | 36.48B |
| Revenue (ttm) | 4.56B |
| Net Income (ttm) | -177.64M |
| EPS (ttm) | -1.68 |
| PE Ratio (ttm) | -203.19 |
| Forward PE | 49.43 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 429.9 |
| Volume | 85,520 |
| Avg. Volume (20D) | 364,180 |
| Open | 339.11 |
| Previous Close | 345.17 |
| Day's Range | 335.12 - 342.54 |
| 52-Week Range | 170.99 - 355.30 |
| Beta | 0.21 |
| Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for ONC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsBeOne Medicines Ltd. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+8.49%
BeOne Medicines shares are trading higher after th...
Unlock content with
Pro Subscription
1 month ago
+2.72%
BeOne Medicines shares are trading higher after the company announced topline results from a Phase 1/2 study of sonrotoclax in adult patients with relapsed/refractory mantle cell lymphoma, following treatment with a Bruton's tyrosine kinase inhibitor and anti-CD20 therapy.
1 month ago · fool.com
BeOne Medicines (ONC) Q2 EPS Soars 924%BeOne Medicines (ONC) Q2 EPS Soars 924%
